Affinity Asset Advisors, LLC 13F 持仓 · 2026年Q2
Affinity Asset Advisors 在 2026年Q2（报告期截至 2026-06-30）的 SEC 13F 申报中报告了 103 只证券，申报市值合计 22.12 亿美元。前几大持仓：ROIV（6.00%）、APGE（5.92%）、SYRE（5.13%）。本季前 25 大持仓中：新建仓 2 只、增持 12 只、减持 9 只。
| 排名 | 代码 | 公司 | 市值 | 占组合 | 股数 | 变动 |
|---|---|---|---|---|---|---|
| 1 | ROIV | ROIVANT SCIENCES LTD | $132.7M | 6.00% | 3.8M | 增持 |
| 2 | APGE | APOGEE THERAPEUTICS INC | $131.0M | 5.92% | 987,000 | 减持 |
| 3 | SYRE | SPYRE THERAPEUTICS INC | $113.6M | 5.13% | 1.3M | 持平 |
| 4 | ERAS | ERASCA INC | $96.2M | 4.35% | 5.2M | 减持 |
| 5 | XENE | XENON PHARMACEUTICALS INC | $96.3M | 4.35% | 1.6M | 减持 |
| 6 | ALKS | ALKERMES PLC | $72.0M | 3.26% | 1.4M | 增持 |
| 7 | INSM | INSMED INC | $69.3M | 3.13% | 650,000 | 增持 |
| 8 | MRNA | MODERNA INC | $68.3M | 3.09% | 975,000 | 增持 |
| 9 | PRAX | PRAXIS PRECISION MEDICINES I | $61.9M | 2.80% | 185,000 | 增持 |
| 10 | ORKA | ORUKA THERAPEUTICS INC | $56.2M | 2.54% | 590,000 | 增持 |
| 11 | ANAB | ANAPTYSBIO INC | $55.8M | 2.52% | 826,109 | 减持 |
| 12 | AVTX | AVALO THERAPEUTICS INC | $53.6M | 2.42% | 2.9M | 增持 |
| 13 | CYTK | CYTOKINETICS INC | $46.9M | 2.12% | 550,000 | 减持 |
| 14 | RVMD | REVOLUTION MEDICINES INC | $46.8M | 2.12% | 250,000 | 增持 |
| 15 | ABVX | ABIVAX SA | $44.0M | 1.99% | 330,000 | 减持 |
| 16 | TRAX | FIRST TRACKS BIOTHERAPEUTICS | $40.9M | 1.85% | 2.0M | 新建仓 |
| 17 | DNTH | DIANTHUS THERAPEUTICS INC | $39.0M | 1.76% | 400,000 | 持平 |
| 18 | STRO | SUTRO BIOPHARMA INC | $38.9M | 1.76% | 1.2M | 增持 |
| 19 | NUVL | NUVALENT INC | $34.0M | 1.54% | 275,000 | 减持 |
| 20 | TRVI | TREVI THERAPEUTICS INC | $33.6M | 1.52% | 1.8M | 减持 |
| 21 | ARKG | ARK ETF TR | $31.5M | 1.43% | 750,000 | 新建仓 |
| 22 | OVID | OVID THERAPEUTICS INC | $27.3M | 1.23% | 10.1M | 减持 |
| 23 | LXEO | LEXEO THERAPEUTICS INC | $27.0M | 1.22% | 5.8M | 增持 |
| 24 | CLDX | CELLDEX THERAPEUTICS INC NEW | $26.0M | 1.18% | 700,000 | 增持 |
| 25 | BLTE | BELITE BIO INC | $25.4M | 1.15% | 165,000 | 增持 |
来源：SEC 13F 申报文件 · 截至 2026-06-30
本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR